Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
Sonoma Pharmaceuticals (NASDAQ:SNOA) has announced the successful registration of its hypochlorous acid-based acne products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA). The company will launch its products through a major UK pharmacy chain, reaching over 1,200 stores nationwide.
The product line features an acne toner and balancing serum, which will be marketed under the retailer's private label brand. These products are based on Sonoma's patented Microcyn technology, utilizing stabilized hypochlorous acid (HOCl). The formulation offers a natural alternative to traditional acne treatments containing alcohol and benzoyl peroxide.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha annunciato la registrazione con successo dei suoi prodotti per l'acne a base di acido ipocloroso presso la Medicines & Healthcare products Regulatory Agency (MHRA) del Regno Unito. L'azienda lancerà i suoi prodotti attraverso una grande catena di farmacie britanniche, raggiungendo oltre 1.200 negozi in tutto il paese.
La linea di prodotti comprende un tonico per l'acne e un siero riequilibrante, che saranno commercializzati sotto il marchio privato del rivenditore. Questi prodotti si basano sulla tecnologia brevettata Microcyn di Sonoma, che utilizza acido ipocloroso stabilizzato (HOCl). La formulazione offre un'alternativa naturale ai trattamenti tradizionali per l'acne contenenti alcol e perossido di benzoile.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha anunciado la exitosa inscripción de sus productos para el acné a base de ácido hipocloroso ante la Agencia Reguladora de Medicamentos y Productos Sanitarios del Reino Unido (MHRA). La compañía lanzará sus productos a través de una importante cadena de farmacias del Reino Unido, llegando a más de 1.200 tiendas en todo el país.
La línea de productos incluye un tónico para el acné y un suero equilibrante, que se comercializarán bajo la marca privada del minorista. Estos productos están basados en la tecnología patentada Microcyn de Sonoma, que utiliza ácido hipocloroso estabilizado (HOCl). La formulación ofrece una alternativa natural a los tratamientos tradicionales para el acné que contienen alcohol y peróxido de benzoilo.
Sonoma Pharmaceuticals (NASDAQ:SNOA)는 영국 의약품 및 의료제품 규제 기관(MHRA)에 자사의 차아염소산 기반 여드름 제품 등록에 성공했다고 발표했습니다. 이 회사는 영국 내 주요 약국 체인을 통해 제품을 출시하여 전국 1,200개 이상의 매장에 진출할 예정입니다.
제품 라인에는 여드름 토너와 밸런싱 세럼이 포함되어 있으며, 소매업체의 자체 브랜드로 판매됩니다. 이 제품들은 Sonoma의 특허 기술인 Microcyn 기술을 기반으로 하며, 안정화된 차아염소산(HOCl)을 사용합니다. 이 제형은 알코올과 벤조일 퍼옥사이드가 포함된 기존 여드름 치료제에 대한 자연스러운 대안을 제공합니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a annoncé l'enregistrement réussi de ses produits anti-acné à base d'acide hypochloreux auprès de la Medicines & Healthcare products Regulatory Agency (MHRA) du Royaume-Uni. L'entreprise lancera ses produits via une grande chaîne de pharmacies britannique, atteignant plus de 1 200 magasins à l'échelle nationale.
La gamme de produits comprend un tonique anti-acné et un sérum équilibrant, qui seront commercialisés sous la marque de distributeur du détaillant. Ces produits reposent sur la technologie brevetée Microcyn de Sonoma, utilisant de l'acide hypochloreux stabilisé (HOCl). La formulation offre une alternative naturelle aux traitements traditionnels de l'acné contenant de l'alcool et du peroxyde de benzoyle.
Sonoma Pharmaceuticals (NASDAQ:SNOA) hat die erfolgreiche Registrierung seiner auf hypochloriger Säure basierenden Akneprodukte bei der britischen Arzneimittel- und Gesundheitsprodukte-Regulierungsbehörde (MHRA) bekannt gegeben. Das Unternehmen wird seine Produkte über eine große Apothekenkette im Vereinigten Königreich vertreiben und damit über 1.200 Filialen landesweit erreichen.
Die Produktlinie umfasst ein Akne-Tonikum und ein ausgleichendes Serum, die unter der Eigenmarke des Händlers vermarktet werden. Diese Produkte basieren auf der patentierten Microcyn-Technologie von Sonoma, die stabilisierte hypochlorige Säure (HOCl) verwendet. Die Formulierung bietet eine natürliche Alternative zu herkömmlichen Aknebehandlungen mit Alkohol und Benzoylperoxid.
- Expansion into UK market through 1,200+ retail locations
- Successful regulatory approval from MHRA
- Strategic partnership with major UK pharmacy chain
- Private label agreement potentially indicating long-term retail commitment
- Products will be sold under retailer's brand, potentially limiting brand recognition
- No financial terms or revenue projections disclosed
BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom.
The innovative product line includes an acne toner and a balancing serum, both of which are available under the retailer's own brand name.
"We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What new products has Sonoma Pharmaceuticals (SNOA) registered in the UK?
How many UK stores will carry Sonoma Pharmaceuticals' (SNOA) new acne products?
What is the key technology behind SNOA's new acne products?
Will Sonoma Pharmaceuticals' (SNOA) acne products be sold under their own brand name in the UK?
